Tracer library / [111In]In-PSMA-617
[111In]In-PSMA-617
Also written as [111In]In-PSMA-617; [In-111]In-PSMA-617; PSMA-617; PSMA617
- Radionuclide
- In-111 t½ 4032 min
- Modality
- SPECT
- Production route
- Cyclotron solid target
- Stage
- Research
- Syntheses indexed
- 0
What it is
- Compound class
- Small molecule (urea-based)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 37241763 / DOI 10.3390/molecules28104022
- Clinical application
- Research SPECT imaging of PSMA-positive prostate cancer; PSMA-617 is the targeting vector of the approved therapeutic [177Lu]Lu-PSMA-617 PMID 37241763 / DOI 10.3390/molecules28104022
- Theranostic pair
- [177Lu]Lu-PSMA-617
Regulatory status
- FDA
- No Drugs@FDA / openFDA drug registry — no approved application found; search: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=In-111+PSMA-617
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Published syntheses
No synthesis has been parsed for this agent yet.
Precursor
- Common precursor
- DOTA-conjugated PSMA ligand PSMA-617 PMID 37241763 / DOI 10.3390/molecules28104022
- Suppliers seen in the literature
- —
- Typical final purification
- SPE
Need this precursor?We can point you to suppliers for [111In]In-PSMA-617, or handle the enquiry for you.
Get in touchQuality control Preliminary - inferred from compound class
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [111In]In-PSMA-617.
Get in touch